World journal of gastroenterology · 2025
HLA-C*03:04:01 and HLA-B*15:18:01 but not HLA-DQA1*05 associated with anti- tumor necrosis factor antibody formation in Taiwanese inflammatory bowel disease patients.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Weng Meng-Tzu, Yao Chi-Yuan, Lin Wei-Chen, Lai Sheng-Kai, Tung Chien-Chih, Wang Chun-Ying, Wong Jau-Min, Chen Pei-Lung, Wei Shu-Chen
Аннотация
BACKGROUND: Anti-drug antibodies (ADAs) can reduce the effectiveness of biologics. While human leukocyte antigen (HLA)-DQA1*05 allele is linked to ADA formation in European Crohn's disease patients, its relevance in non-European populations remains unclear.
AIM: To investigate HLA genotypes associated with the development of ADAs in Taiwanese inflammatory bowel disease (IBD) patients treated with biologics.
METHODS: In this multicenter study, IBD patients treated with anti-tumor necrosis factor (TNF), anti-integrin, or anti-interleukin (IL)-12/23 therapies from April 2022 to June 2024 were enrolled. All participants underwent next-generation sequencing for HLA genotyping. ADA levels were measured via enzyme linked immunosorbent assay. HLA allele frequencies were compared between ADA-positive and ADA-negative groups, and against general Taiwanese population data.
RESULTS: Ninety-five IBD patients were included: 58 received anti-TNF therapy (38 infliximab, 20 adalimumab), 27 anti-integrin, and 10 anti-IL-12/23. ADAs occurred only in the anti-TNF group (n = 22): 19 infliximab (50%) and 3 adalimumab (15%). No ADAs developed in patients on anti-integrin or anti-IL-12/23 agents. HLA-C*03:04:01 was significantly associated with anti-infliximab ADAs (31.6% vs 0%, P = 0.02), and HLA-B*15:18:01 with anti-adalimumab ADAs (66.7% vs 0%, P = 0.016). HLA-DQA1*05 was not associated with ADA formation. Frequencies of HLA-C*03:04:01 (8.4% vs 10.5%) and HLA-B*15:18:01 (1.6% vs 0.6%) in IBD patients were comparable to those in the general population. ADA titers were inversely correlated with serum drug levels.
CONCLUSION: In Taiwanese IBD patients, HLA-C*03:04:01 and HLA-B*15:18:01 were significantly associated with ADA development to infliximab and adalimumab, respectively. HLA-DQA1*05 was not predictive, highlighting ethnic differences in genetic predisposition to immunogenicity.
AIM: To investigate HLA genotypes associated with the development of ADAs in Taiwanese inflammatory bowel disease (IBD) patients treated with biologics.
METHODS: In this multicenter study, IBD patients treated with anti-tumor necrosis factor (TNF), anti-integrin, or anti-interleukin (IL)-12/23 therapies from April 2022 to June 2024 were enrolled. All participants underwent next-generation sequencing for HLA genotyping. ADA levels were measured via enzyme linked immunosorbent assay. HLA allele frequencies were compared between ADA-positive and ADA-negative groups, and against general Taiwanese population data.
RESULTS: Ninety-five IBD patients were included: 58 received anti-TNF therapy (38 infliximab, 20 adalimumab), 27 anti-integrin, and 10 anti-IL-12/23. ADAs occurred only in the anti-TNF group (n = 22): 19 infliximab (50%) and 3 adalimumab (15%). No ADAs developed in patients on anti-integrin or anti-IL-12/23 agents. HLA-C*03:04:01 was significantly associated with anti-infliximab ADAs (31.6% vs 0%, P = 0.02), and HLA-B*15:18:01 with anti-adalimumab ADAs (66.7% vs 0%, P = 0.016). HLA-DQA1*05 was not associated with ADA formation. Frequencies of HLA-C*03:04:01 (8.4% vs 10.5%) and HLA-B*15:18:01 (1.6% vs 0.6%) in IBD patients were comparable to those in the general population. ADA titers were inversely correlated with serum drug levels.
CONCLUSION: In Taiwanese IBD patients, HLA-C*03:04:01 and HLA-B*15:18:01 were significantly associated with ADA development to infliximab and adalimumab, respectively. HLA-DQA1*05 was not predictive, highlighting ethnic differences in genetic predisposition to immunogenicity.